These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24518104)

  • 1. Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey.
    Pansieri C; Pandolfini C; Elie V; Turner MA; Kotecha S; Jacqz-Aigrain E; Bonati M
    Sci Rep; 2014 Feb; 4():4076. PubMed ID: 24518104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial of azithromycin to eradicate
    Viscardi RM; Terrin ML; Magder LS; Davis NL; Dulkerian SJ; Waites KB; Ambalavanan N; Kaufman DA; Donohue P; Tuttle DJ; Weitkamp JH; Hassan HE; Eddington ND
    Arch Dis Child Fetal Neonatal Ed; 2020 Nov; 105(6):615-622. PubMed ID: 32170033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antenatal azithromycin for Ureaplasma spp. on neonatal outcome at ≤30 weeks' gestational age.
    Kim SH; Chun J; Ko KH; Sung TJ
    Pediatr Int; 2019 Jan; 61(1):58-62. PubMed ID: 30460724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis.
    Nair V; Loganathan P; Soraisham AS
    Neonatology; 2014; 106(4):337-47. PubMed ID: 25278176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial.
    Ballard HO; Shook LA; Bernard P; Anstead MI; Kuhn R; Whitehead V; Grider D; Crawford TN; Hayes D
    Pediatr Pulmonol; 2011 Feb; 46(2):111-8. PubMed ID: 20963840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.
    Viscardi RM; Othman AA; Hassan HE; Eddington ND; Abebe E; Terrin ML; Kaufman DA; Waites KB
    Antimicrob Agents Chemother; 2013 May; 57(5):2127-33. PubMed ID: 23439637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.
    Hassan HE; Othman AA; Eddington ND; Duffy L; Xiao L; Waites KB; Kaufman DA; Fairchild KD; Terrin ML; Viscardi RM
    J Clin Pharmacol; 2011 Sep; 51(9):1264-75. PubMed ID: 21098694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Ureaplasma infection pattern and azithromycin treatment effect with bronchopulmonary dysplasia in Ureaplasma positive infants: a cohort study.
    Chen X; Huang X; Lin Y; Lin B; Yang C; Huang Z; Yang C
    BMC Pulm Med; 2023 Jun; 23(1):229. PubMed ID: 37365524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development.
    Turner MA; Jacqz-Aigrain E; Kotecha S
    Arch Dis Child; 2012 Jun; 97(6):573-7. PubMed ID: 21697219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ureaplasma and bronchopulmonary dysplasia.
    Gancia P; Delogu A; Pomero G
    Early Hum Dev; 2014 Mar; 90 Suppl 1():S39-41. PubMed ID: 24709455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of biofilm formation in Ureaplasma antibiotic susceptibility and development of bronchopulmonary dysplasia in preterm neonates.
    Pandelidis K; McCarthy A; Chesko KL; Viscardi RM
    Pediatr Infect Dis J; 2013 Apr; 32(4):394-8. PubMed ID: 23114371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.
    Merchan LM; Hassan HE; Terrin ML; Waites KB; Kaufman DA; Ambalavanan N; Donohue P; Dulkerian SJ; Schelonka R; Magder LS; Shukla S; Eddington ND; Viscardi RM
    Antimicrob Agents Chemother; 2015 Jan; 59(1):570-8. PubMed ID: 25385115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques.
    Schelonka RL; Katz B; Waites KB; Benjamin DK
    Pediatr Infect Dis J; 2005 Dec; 24(12):1033-9. PubMed ID: 16371861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of Ureaplasma urealyticum in bronchopulmonary dysplasia of prematurity].
    Bao Y; Zhao ZY; Shi LP; Ma XL; Chen Z; Luo F
    Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):767-70. PubMed ID: 23302568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin for preventing bronchopulmonary dysplasia in preterm infants: A systematic review and meta-analysis.
    Razak A; Alshehri N
    Pediatr Pulmonol; 2021 May; 56(5):957-966. PubMed ID: 33382534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ureaplasma and BPD.
    Kallapur SG; Kramer BW; Jobe AH
    Semin Perinatol; 2013 Apr; 37(2):94-101. PubMed ID: 23582963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospital variation and risk factors for bronchopulmonary dysplasia in a population-based cohort.
    Lapcharoensap W; Gage SC; Kan P; Profit J; Shaw GM; Gould JB; Stevenson DK; O'Brodovich H; Lee HC
    JAMA Pediatr; 2015 Feb; 169(2):e143676. PubMed ID: 25642906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Administration of intrapartum erythromycin for the interruption of the vertical transmission of Ureaplasma urealyticum and its possible relation to the development of bronchopulmonary dysplasia in neonates with less than 32 weeks gestation. Multicenter study].
    Salcedo Abizanda S; Cabero Roura L; Andreu Domingo A; Lucaya Layret J; Perapoch López J; Casellas Caro M; Fernández Pérez F; Campins Martí M; Torán Fuentes N; Peguero Monforte G
    An Esp Pediatr; 1997 Jun; Spec No 1():73-7. PubMed ID: 9382274
    [No Abstract]   [Full Text] [Related]  

  • 19. Macrolides do not affect the incidence of moderate and severe bronchopulmonary dysplasia in symptomatic ureaplasma-positive infants.
    Anbu Chakkarapani A; Paes B; Shivananda S
    Acta Paediatr; 2015 Oct; 104(10):e427-32. PubMed ID: 26109378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azithromycin for Eradication of
    Chang E; Ballard KE; Johnson PN; Nandyal R; Miller JL
    J Pediatr Pharmacol Ther; 2023; 28(1):10-19. PubMed ID: 36777984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.